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Novelty and impact of the work (75 = 75 words): Our study examined cancer survival trends in 1992-
2009 for most frequent cancers in HIV-infected individuals and provided a comparison to cancer survival 
estimates in the general population in France. Survival improved for Kaposi sarcoma, non-Hodgkin 
lymphoma, Hodgkin lymphoma and liver cancer and remained stable for lung and anal cancers in the 
recent periods, with a survival similar to the general population for solid tumours and poorer than the 
general population for haematological malignancies in 2001-2004.  
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ABSTRACT 
 
Although the decline in cancer mortality rates with the advent of combination antiretroviral therapy 
(cART) in HIV-infected individuals can be mostly explained by a decrease in cancers incidence, we 
looked here if improved survival after cancer diagnosis could also contribute to this decline. Survival 
trends were analyzed for most frequent cancers in the HIV-infected population followed in the French 
Hospital Database on HIV: 979 and 2760 cases of visceral and non-visceral Kaposi's sarcoma (KS), 2339 
and 461 cases of non-Hodgkin lymphoma (NHL) and Hodgkin's lymphoma (HL), 446 lung, 312 liver and 
257 anal cancers. Five-year Kaplan-Meier survival rates were estimated for four periods: 1992-1996, 
1997-2000, 2001-2004 and 2005-2009. Cox proportional hazard models were used to compare survival 
across the periods, after adjustment for confounding factors. For 2001-2004, survival was compared to 
the general population after standardization on age and sex. Between the pre-cART (1992-1996) and early-
cART (1997-2000) periods, survival improved after KS, NHL, HL and anal cancer and remained stable 
after lung and liver cancers. During the cART era, 5-year survival improved after visceral and non-visceral 
KS, NHL, HL and liver cancer, being 83%, 92%, 65%, 87% and 19% in 2005-2009 respectively, and 
remained stable after lung and anal cancers, being 16% and 65% respectively. Compared with the general 
population, survival in HIV-infected individuals in 2001-2004 was poorer for hematological malignancies 
and similar for solid tumors. For hematological malignancies, survival continues to improve after 2004, 
suggesting that the gap between the HIV-infected and general populations will close in the future.   
5 
 
INRODUCTION 
HIV-infected individuals are at increased risk of several malignancies (1–3). Despite a decline in their 
incidence since the advent of combination antiretroviral therapy (cART) in 1996, AIDS-defining cancers 
(ADCs: Kaposi’s sarcoma (KS), non-Hodgkin lymphoma (NHL) and cervical cancer) remained more 
frequent in HIV-infected individuals than in the general population in the recent cART period (1,2). The 
risk of the most frequent non AIDS-defining cancers (NADCs) also remains 3 to 47 times higher than in 
the general population (1–3).  
Overall survival has improved since the advent of cART (4,5), due to a decline in mortality from both 
AIDS-defining and non AIDS-defining causes including cancers (6). Part of this decline might be 
explained by improved survival after cancer diagnosis. Several studies have shown improved survival 
after diagnosis of KS (7–9) and NHL (7,9–15) since the advent of cART. The few studies that have 
examined trends in cancer survival have given conflicting results for HL (16,17) and anal cancer 
(15,17,18), and no improvement for lung cancer (15,17). Most of these studies compared survival between 
the pre-cART and early cART periods (10–16). Recently, a study comparing cancer patients with AIDS 
with HIV-seronegative cancer patients showed that survival after cancer diagnosis had improved in the 
cART era, reducing the survival gap between the  2 populations from 5-fold (HR = 5.1; 95% CI [4.3-6.1]) 
in the pre-cART period to 3-fold (HR = 2.9; 95% CI [2.6-3.3]) in the cART period (19). However, results 
for AIDS patients cannot be generalized to all HIV-infected patients, as patients with AIDS in the pre-
cART era differ from their counterparts in the cART era. Indeed, in the pre-cART era most individuals 
with HIV infection progressed to AIDS, while this is now mainly the case of only late-diagnosed patients. 
It is therefore important to examine temporal trends in survival after cancer diagnosis in all HIV-infected 
individuals. 
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As survival trends for ADCs and NADCs have rarely been studied, and as no data are available for 
individual NADCs, we examined time trends in survival after diagnosis for each of the six most frequent 
cancers, using data from the French Hospital Database on HIV (FHDH ANRS-CO4) collected from 1992 
through 2009. We then compared survival among HIV-infected individuals to age- and sex-standardized 
survival in individuals with cancer in the general population in France in 2001-2004.  
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MATERIAL AND METHODS 
The FHDH (20) is an ongoing, open, prospective cohort created in 1989, with participation by 70 general 
and university hospitals in France. The only inclusion criteria are HIV type 1 (HIV-1) or type 2 (HIV-2) 
infection and written informed consent. Among HIV-1 infected patients aged between 15 and 84 years at 
FHDH enrollment and followed-up between 1992 and 2009, we selected individuals diagnosed with 
cancer during this period. Patients who had no available CD4 cell count during the 12 months prior to 
cancer diagnosis were excluded. If several CD4 cell counts were available during this period, the last one 
was used in the analysis. 
We examined the most frequent cancers diagnosed among HIV-infected individuals, namely KS, NHL, 
HL, and lung, liver, and anal cancer. As the prognosis of KS is worse for visceral forms, we separately 
analyzed visceral (mostly lung, gastrointestinal, or multiple organs) and non-visceral KS (skin, skin 
structures, palate and lymph nodes). The International Classification of Diseases, Ninth Revision (ICD-9) 
was used to code cancers in FHDH before 1997 and the Tenth Revision (ICD-10) thereafter 
(Supplementary table 1). For KS, NHL and HL, results of regular audits comparing data in the FHDH 
with those in the corresponding medical records showed that >90 % of recorded cases corresponded to 
histology proven cancer cases. Specific research projects implemented in the cohort showed that 95% of 
the recorded cases of lung cancer between 2000 and 2010 and 87% of the recorded cases of anal cancer 
between 1992 and 2008 were confirmed by histological findings in the medical records. For liver cancer, 
the diagnosis is based on liver imagery and the level of alpha-fetoprotein, but no validation study has been 
performed for this cancer. Deaths for the HIV-infected individuals were recorded in the FHDH according 
to the vital status in patients’ medical records. Cancer diagnoses were grouped into the pre- (1992-1996), 
early- (1997-2000), intermediate- (2001-2004) and late-cART periods (2005-2009).  
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Death from all causes was the analyzed event, while patients alive at the last visit to an FHDH center or 5 
years after cancer diagnosis (whichever occurred earlier) were censored. The Kaplan-Meier method was 
used to estimate 5-year survival after cancer diagnosis during the four periods, and the log-rank test was 
used to analyze differences in survival. Multivariate Cox proportional hazard models were used to evaluate 
the calendar-period effect on the risk of death, using the period 1997-2000 as reference. First, we adjusted 
Cox models for sex and age at diagnosis. Second, to determine whether changes in survival were 
influenced by changes in patient characteristics over time, we also included the following characteristics 
known to impact survival among HIV-infected individuals and which might have changed over time: sex, 
age at cancer diagnosis, geographic origin, HIV transmission group, region of care, hepatitis C virus 
(HCV) co-infection, hepatitis B virus (HBV) co-infection, AIDS status, and CD4 cell count at cancer 
diagnosis. Additional analyses were performed during the cART era (1997-2009), with further adjustment 
for viral load at cancer diagnosis. HIV viral load was not available in the pre-cART era before 1997.  
Finally, to compare survival between HIV-infected individuals and the general population we used the 
latest data available in the French network of cancer registries (FRANCIM) in 2001-2004 (21-23). For 
persons with cancer in the general population, FRANCIM collected information on deaths, first by 
contacting the municipality of birth which compiles deaths reporting for all individuals born in the city, 
and the National Institute of Statistics and Economic Studies (Insee) which collects declaration of death 
together with the national identity number. When vital status was not known by these two queries, other 
sources were used as medical records, the municipality of residence or health insurance.  
Because the age and sex distributions differ between the HIV-infected and general populations (1), 5-year 
survival in the general population was standardized for each cancer by using the direct method, based on 
the age and sex structure of HIV-infected patients diagnosed with the same cancer. Moreover for NHL, 
because histologic subtypes of NHL in HIV patients are mostly B subtypes (24), with about 44% of HIV-
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infected individuals with NHL having diffuse large B-cell lymphoma (DLBCL) subtype in France (C 
Besson PI of the ANRS CO16 Lymphovir cohort, personal communication), we standardized survival in 
general population for all NHL subtypes, and also restricted the analysis to DLBCL. A t-test was used to 
compare 5-year survival between HIV-infected individuals and the French general population. For KS, 
this analysis was not performed because data were not available in the general population.  
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RESULTS 
Among 99 818 HIV-1-infected individuals enrolled in the FHDH between 1992 and 2009, 6138 AIDS-
defining cancers (visceral and non-visceral KS and NHL) and 1510 non AIDS-defining cancers were 
diagnosed. We excluded 94 individuals with cancer with no available CD4 cell count during the 12 months 
before diagnosis (60 with KS or NHL, of whom 50 died; and 34 with a NADC, of whom 26 died). The 
analysis included 979 cases of visceral KS, 2760 non visceral KS, 2339 NHL and 1476 NADCs. The HIV-
infected individuals' characteristics at cancer diagnosis are shown in Table 1. Men who have sex with men 
accounted for most cases of KS and anal cancer, while intravenous drug users (IDU) accounted for most 
cases of liver cancer. The median time since HIV diagnosis was longer among patients with NADCs (11 
years) than among those with ADCs (6 years). Patients with KS and NHL had a median CD4 cell count 
below 100/mm3 at cancer diagnosis and also the lowest nadir CD4 cell counts. Among patients with 
NADCs, those with anal cancer had the lowest nadir CD4 cell counts but their median count at diagnosis 
was within the range of median counts among patients with other NADCs. The proportions of patients 
who had been on cART for at least 6 months at cancer diagnosis were below 40% for KS and NHL, and 
above 50% for the other cancers. 
Kaplan-Meier survival distributions according to the period of cancer diagnosis are shown in Figure 1 (KS 
and NHL) and Figure 2 (NADCs). Five-year Kaplan-Meier survival rates and adjusted 5-year hazard ratios 
(HR) of death are shown in Table 2 according to the period of cancer diagnosis in the period 1992-2009, 
and in Table 3 for the period 1997-2009. 
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AIDS-defining cancers 
Between the pre-cART and late cART periods, 5-year survival rates rose from 14% to 83% after visceral 
KS, from 36% to 92% after non visceral KS, and from 15% to 65% after NHL (Figure 1). As shown in 
Table 2, in analyses adjusted for age and sex, the 5-year cancer mortality declined significantly between 
the pre-cART and early cART periods; similar decline was observed after adjustment for all the other 
potential confounders, with a HR in 1992-1996 compared to 1997-2000 of 2.34 for visceral KS, 3.19 for 
non-visceral KS and 1.38 for NHL. The 5-year cancer mortality, adjusted for age and sex, also declined 
significantly during the cART era for KS whether visceral or non-visceral and for NHL (Table 3). After 
adjustment for all confounders, the 5-year adjusted HR of death was reduced by around 2-fold in the late-
cART period compared to the early-cART period, and the reduction was significant for NHL (Ptrend 
<0.0001) and non-visceral KS (Ptrend=0.0269) and was not significant for visceral KS (Ptrend=0.3233).  
Non AIDS-defining cancers 
As shown in Figure 2, between the pre-cART and late cART periods, 5-year survival increased 
significantly from 48% to 87% after HL and from 17% to 19% after liver cancer. For lung and anal cancers, 
the difference in the 5-year survival distributions was not statistically significant across the calendar 
periods, with an overall 5-year survival rate of 16% after lung cancer and 65% after anal cancer during 
the entire study period.  
In analyses adjusted for age and sex, the 5-year HR of death after HL diagnosis was 1.62 (95% CI [1.04-
2.53]) in the pre-cART period compared to the early cART period (Table 2), but an improvement in 
survival was observed during the cART era even after adjustment for all confounders including viral load 
at HL diagnosis (Ptrend =0.0071) (Table 3). For lung cancer, the adjusted 5-year HR of death remained 
stable across the calendar periods. In analyses adjusted for age and sex, the 5-year HR of death after liver 
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cancer did not change significantly between the pre-cART and early cART periods (Table 2). During the 
cART era, survival after liver cancer diagnosis improved after adjustment for potential confounders (Ptrend 
=0.0198), but was no longer significantly improved after adjustment for viral load (Ptrend =0.2237) (Table 
3). In the fully adjusted model, the 5-year HR of death after anal cancer diagnosis was 3.22 (95% CI [1.02-
10.09]) in the pre-cART period compared to the early cART period (Table 2), but there was no significant 
change during the cART era (Ptrend =0.7239) (Table 3).  
Comparison with the general population 
For cases diagnosed in 2001-2004, Table 4 shows 5-year crude survival rates for the general population 
in the first column, 5-year standardized survival rates for the general population in the second column and 
5-year survival rates for the HIV-infected population in the third column, with respect to NHL, lung 
cancer, HL, liver cancer and anal cancer. For NHL, the standardized 5-year survival rate in the general 
population was estimated at 74% for all subtypes, being 70% for DLBCL subtype (Table 4). The age- and 
sex-standardized survival rate was higher in the general population than among HIV-infected individuals 
with respect to NHL (either for all subtypes or DLCBL subtype) and HL. Regarding solid tumors, 5-year 
survival rates among HIV-infected individuals were close to age- and sex-standardized rates in the general 
population.  
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DISCUSSION 
Using data from FHDH with a longitudinal follow up of 20 years, we observed improved survival with 
the advent of cART and during the cART period among HIV-infected individuals diagnosed with KS and 
NHL. The advent of cART had no apparent impact on survival after HL, but survival after diagnosis of 
this cancer improved during the cART era. Regarding solid tumors, the only improvement in survival 
between the pre-cART and early cART periods concerned anal cancer. During the cART era, survival 
after liver cancer improved very modestly mainly because of better control of HIV viral load, while 
survival after lung and anal cancer was stable. Among HIV-infected individuals diagnosed with 
hematological malignancies in 2001-2004, survival was less favorable than in the general population, 
whereas survival among patients diagnosed with solid tumors during the same period was similar to that 
in the general population. From a methodological point of view our study highlights that accounting for 
the age and sex survival distribution in the general population is essential when comparing survival in 
HIV-infected patients to that of the general population. Table 4 nicely shows that not accounting for it 
would have been misleading for NHL, liver and anal cancer. 
 
Major strengths of this work are the lengthy study period (nearly 20 years, including 15 years of cART 
use), the large number of cases (allowing us to study survival separately for each malignancy), the 
inclusion of all HIV-infected individuals (not only patients with AIDS), and the availability of many 
covariates known to influence the progression of HIV infection. The relationship between temporal 
changes in survival after cancer diagnosis and changes in cancer stage at diagnosis and cancer 
management could not be evaluated, as the data were not available. FHDH linkage with the French death 
registry is not authorized. Therefore, deaths, particularly from non AIDS-defining causes, may have 
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slightly been under-reported (20), leading to a slight overestimation of cancer survival in HIV-infected 
individuals. This bias could have a small effect on survival difference between the HIV-infected and 
general populations. For hematological malignancies, the survival difference may have been slightly 
broadened. But for lung and liver cancers, we believe that the impact of death under-notification was 
minimal as survival was very poor in both populations. 
Another limitation of the study is not taking into account of the causes of death in the analyses, although, 
in patients with multiple co-morbidities, the collected causes of death could often be incorrect, incomplete 
or impossible to dismantle. For instance, for HIV-infected persons who have cancer, the collected cause 
of death could be the HIV infection, the cancer itself, the complications of the cancer treatment, or other 
causes. It is therefore difficult to rely on these data to ascertain the cause of death, and to determine 
whether differences, if any, in overall mortality between the HIV-infected and general populations are due 
to cancer-specific or HIV-specific mortality or both. However, the adjusted models (Table 3) give an 
insight of whether the improvements in survival over time, if any, are related to better cancer treatment or 
better treatment of HIV. Indeed, as CD4 cell count and HIV viral load depend strongly on HIV treatment 
adjusting for CD4 cell count and HIV viral load account for the evolution of the HIV-specific mortality 
that depends on the improvement in HIV treatment. Therefore, we think that the remaining effect on the 
evolution of survival after adjusting for CD4 cell count and HIV viral load is more likely explained by the 
change over time in the cancer treatment in the HIV-infected persons. 
 
The improvement in survival after KS diagnosis is consistent with that seen in other studies comparing 
the pre-cART era with the cART era (7–9). Interestingly, we found that survival improved after diagnosis 
of both visceral and non-visceral KS. The continued improvement in survival during the cART period 
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among patients diagnosed with visceral KS was likely explained by the increasing proportion of HIV-
infected individuals receiving antiretroviral therapy (25). 
As observed in other studies, survival after NHL diagnosis improved between the pre-cART and early 
cART periods (9–15), and continued to improve during the cART era (until 2009). Between the pre- and 
early-cART periods, the improvement in survival after HL was nearly significant and survival improved 
during the cART era. This improvement in survival is similar to that reported by a single institution in 
France specialized in the treatment of lymphomas in HIV-infected individuals and had long used the same 
treatment protocols as for HIV-seronegative individuals (16). Two prior studies showed no change in 
survival after NHL or HL during the cART period (24,26), probably owing to insufficient statistical power 
and/or to combined analysis of HL and NHL. The improved survival observed here after diagnosis of 
hematological malignancies was not explained by changes in the characteristics of HIV-infected 
individuals over time but rather by a calendar-period effect, likely related to more often use of the same 
cancer treatment protocols as in HIV-uninfected individuals and to a better adherence to these protocols 
because of better tolerability. Despite the clear trend towards improved survival after hematological 
malignancies, we observed a marked difference between the HIV-infected and general populations for 
cases diagnosed in 2001-2004 even when restricting to DLBCL, confirming the results of previous studies 
(15,19,24). Although the improvement in survival could be related to better access to cancer treatment 
over time, suboptimal management of HIV-infected individuals with cancer likely persists in 2001-2004; 
indeed, HIV-seropositive cancer patients do not receive the same number of cycles or the same doses of 
chemotherapy as patients not infected by HIV (27). However, the improved survival found in the recent 
period suggests that survival will become in the future similar to that in the general population. 
Survival trends after diagnosis of solid tumors differed according to the malignancy. Our analysis, based 
on a large number of cases of lung cancer (n=460), showed a stable overall survival rate (15%) between 
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1992 and 2009. This is similar to the rates observed by others during the years 1980-2000 (15). This 
absence of improvement could be explained by the lack of significant advances in lung cancer 
management and persistent high proportion of individuals diagnosed at advanced stages (28,29,30). As in 
other studies (31,32,33), survival among HIV-infected patients was as poor as in the general population 
for cases diagnosed in 2001-2004 (22). 
 
Survival following liver cancer diagnosis did not change with the advent of cART and improved only very 
modestly during the cART period. The latter improvement was mainly explained by the increase over 
time in the proportion of patients with controlled viral load as temporal cancer survival trend was no longer 
significant after adjustment for viral load at cancer diagnosis. To our knowledge, survival trends after the 
diagnosis of liver cancer have never previously been assessed in HIV-infected patients. For cases 
diagnosed in 2001-2004, survival was similar among HIV-infected individuals and the general population, 
in agreement with a previous study (34).  
 
Our results for anal cancer confirm those of a previous study that showed a significant improvement 
between the pre-cART and early cART periods (15): the 5-year HR of death in our study was 3 times 
higher among individuals diagnosed with anal cancer in 1992-1996 than in those diagnosed with this 
cancer in 1997-2000. Another study showed no such change, probably owing to the small number of cases 
(n=26) (18). Nevertheless, we found that survival was stable during the cART era, being similar to that of 
the general population for cases diagnosed in 2001-2004, as previously shown (35).  
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In conclusion, trends in survival after cancer depended on the type of malignancy. We showed a marked 
improvement in the survival of HIV-infected individuals diagnosed with KS. Survival after hematological 
malignancies (NHL and HL) improved over time; in 2001-2004 it remained poorer than in the general 
population, however, there was a considerable improvement in the recent cART period, suggesting that 
survival among HIV-infected individuals will gradually approach that of the general population. There 
was a modest improvement in survival after liver cancer diagnosis during the cART era, while survival 
after lung and anal cancer remained stable: survival was similar to that of the general population for cases 
diagnosed in 2001-2004, and remains poor for lung and liver cancers.   
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Figure legends: 
Figure 1. Kaplan-Meier survival curves following diagnosis of Kaposi's sarcoma and non-Hodgkin 
lymphoma, stratified by calendar period of cancer diagnosis 
Figure 2. Kaplan-Meier survival curves following diagnosis of four non AIDS-defining cancers 
(Hodgkin's lymphoma, lung, liver, anal cancer) stratified by calendar period of cancer diagnosis  
  
26 
 
 
27 
 
  
28 
 
Table 1. Characteristics of HIV-infected individuals at cancer diagnosis. 
 
 
Data are numbers (proportions) and medians (interquartile range). 
 
 
 Visceral Kaposi 
sarcoma 
(979) 
Non-visceral 
Kaposi sarcoma 
(2760) 
Non-Hodgkin 
lymphoma  
(2339) 
Hodgkin's 
lymphoma 
(461) 
Lung 
(446) 
Liver 
(312) 
Anal 
(257) 
Year of diagnosis        
1992-1996 638 (65) 1742 (63) 1088 (47) 92 (20) 36 (8) 20 (6) 8 (3) 
1997-2000 176 (18) 374 (14) 516 (22) 111 (24) 107 (24) 39 (13) 54 (21) 
2001-2004 90 (9) 329 (12) 359 (15) 95 (21) 131 (29) 82 (26) 83 (32) 
2005-2009 75 (8) 315 (11) 376 (16) 163 (35) 172 (39) 171 (55) 112 (44) 
        
Sex         
Men  926 (95) 2614 (95) 1955 (84) 398 (86) 382 (86) 265 (85) 234 (91) 
Women 53 (5) 146 (5) 384 (16) 63 (14) 64 (14) 47 (15) 23 (9) 
        
HIV transmission group  
and geographic origin 
       
Men who have sex with men 718 (73) 2114 (77) 1130 (48) 221 (48) 138 (31) 72 (23) 169 (66) 
Injecting drug users 45 (5) 116 (4) 439 (19) 96 (21) 118 (26) 162 (52) 29 (11) 
Other sub-Saharan 49 (5) 113 (4) 95 (4) 15 (3) 18 (4) 18 (6) 5 (2) 
Other non-sub-Saharan 167 (17) 418 (15) 675 (29) 129 (28) 172 (39) 60 (19) 54 (21) 
        
Age (years) 37 (33-44) 38 (33-45) 39 (33-46) 40 (34-46) 48 (42-56) 47 (42-53) 45 (39-50) 
        
Prior AIDS        
Yes 846 (86) 1115 (40) 1157 (49) 150 (33) 150 (34) 113 (36) 133 (52) 
        
Time since diagnosis of HIV 
infection (years) 
4.7 
(2.1-7.7) 
5.5 
(2.4-8.3) 
6.8 
(3.5-10.1) 
8.1 
(4.2-13.0) 
9.8 
(4.8-14.8) 
14.2 
(9.6-18.5) 
13.2 
(8.8-16.6) 
        
Time since diagnosis of HIV 
infection < 6 months 
106 (11) 262 (9) 153 (7) 21 (5) 21 (5) 9 (3) 4 (2) 
        
HCV co-infection        
Anti-HCV antibody and/or RNA 
positive 
77 (8) 221 (8) 415 (18) 99 (21) 121 (27) 201 (64) 38 (15) 
Negative 428 (44) 1485 (54) 1093 (47) 285 (62) 240 (54) 74 (24) 162 (63) 
Unknown 474 (48) 1054 (38) 831 (35) 77 (17) 85 (19) 37 (12) 57 (22) 
        
HBV co-infection        
Hepatitis B antigen positive 78 (8) 205 (8) 203 (9) 43 (9) 47 (10) 75 (24) 36 (14) 
Negative 454 (46) 1527 (55) 1260 (54) 306 (67) 289 (65) 170 (55) 164 (64) 
Unknown 447 (46) 1028 (37) 876 (37) 112 (24) 110 (25) 67 (21) 57 (22) 
        
Nadir CD4 count (cells per mm3) 15 (5-75) 60 (15-208) 58 (10-170) 141 (43-254) 142 (47-259) 113 (40-202) 87 (18-173) 
        
ARV at cancer diagnosis        
No current ARV 127 (13) 468 (17) 323 (14) 62 (13) 50 (11) 22 (7) 10 (4) 
ARV, not cART 528 (54) 1449 (53) 1008 (43) 86 (19) 63 (14) 42 (13) 23 (9) 
cART < 6 months 165 (17) 365 (13) 256 (11) 51 (11) 31 (7) 14 (5) 14 (5) 
cART ≥ 6 months 159 (16) 478 (17) 752 (32) 262 (57) 302 (68) 234 (75) 210 (82) 
        
CD4 cell count at cancer 
diagnosis (/mm3) 24 (6-104) 65 (16-228) 83 (16-230) 200 (97-384) 301 (161-472) 252 (131-412) 290 (170-493) 
1992-1996 11 (5-48) 34 (10-120) 25 (8-103) 166 (63-292) 175 (76-271) 82 (28-204) 302 (135-458) 
1997-2000 59 (13-172) 161 (42-374) 137 (40-270) 189 (84-366) 250 (130-487) 185 (84-370) 240 (154-336) 
2001-2004 107 (27-220) 160 (51-338) 162 (60-326) 182 (77-366) 278 (140-435) 241 (113-375) 296 (170-466) 
2005-2009 183 (36-325) 247 (88-416) 215 (100-367) 230 (140-423) 371 (204-534) 273 (165-450) 363 (176-551) 
        
HIV RNA load at cancer 
diagnosis (copies/mL) 
4250 
(500-164243) 
11100 
(500-180000) 
5800 
(500-130000) 
500 
(500-9400) 
500 
(500-2370) 
500 
(500-1672) 
500 
(500-7100) 
        
1997-2000 27000  
(500-225000) 
28000 
(500-237308)  
21000 
(663-187375) 
1312 
(500-21000) 
500  
(500-6000) 
500  
(500-15400) 
1645 
(500-28000) 
2001-2004 2060  
(500-173000) 
9323  
(500-198450) 
4000  
(500-114900) 
50  
(50-8600) 
160  
(500-6091) 
139  
(500-8332) 
62  
(500-6360) 
2005-2009 198  
(50-48331) 
3600  
(50-98501) 
299  
(50-64850) 
50  
(50-1300) 
50  
(50-205) 
50  
(50-412) 
50  
(50-2409) 
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Table 2. Five-year Kaplan-Meier survival rates (95% CI) and death hazard ratios (95% CI) after cancer diagnosis between 
1992 and 2009. 
*Models adjusted for sex, age, geographic origin and HIV transmission group, HBV and HCV co-infection, AIDS status, and 
CD4 cell count at cancer diagnosis.  
**Ptrend for the fully adjusted models. 
  
Cancer Diagnosis 
period 
Cases Deaths 
before 5 
years 
5-year srvival % 
(95% CI) 
Death hazard ratio 
adjusted for age and 
sex (95% CI) 
Death hazard ratio 
adjusted for all 
covariates* 
(95% CI) 
Hazard 
Trend** 
P value 
Visceral Kaposi  
 
1992-1996 638 524 14.1 (11.4-17.1) 3.07 (2.42-3.90) 2.34 (1.82-3.01)  
1997-2000 176 80 51.7 (43.8-59.1) 1(ref) 1(ref)  
2001-2004 90 30 64.9 (53.6-74.1) 0.68 (0.45-1.03) 0.88 (0.58-1.35)  
2005-2009 75 12 82.6 (71.3-89.7) 0.32 (0.17-0.59) 0.42 (0.23-0.77) <0.0001 
        
Non-visceral 
Kaposi  
 
1992-1996 1742 1022 35.8 (33.5-38.2) 4.91 (3.83-6.29) 3.19 (2.47-4.10)  
1997-2000 374 67 81.0 (76.5-84.8) 1(ref) 1(ref)  
2001-2004 329 50 83.5 (78.8-87.3) 0.85 (0.59-1.23) 0.90 (0.63-1.31)  
2005-2009 315 22 91.9 (87.7-94.6) 0.40 (0.25-0.65) 0.46 (0.29-0.75) <0.0001 
        
Non Hodgkin 
lymphoma 
 
1992-1996 1088 885 14.8 (12.6-17.1) 2.04 (1.78-2.32) 1.38 (1.20-1.59)  
1997-2000 516 301 37.8 (33.4-42.2) 1(ref) 1(ref)  
2001-2004 359 171 48.7 (43.2-54.0) 0.76 (0.63-0.91) 0.83 (0.69-1.00)  
2005-2009 376 115 65.1 (59.3-70.2) 0.44 (0.36-0.55) 0.52 (0.42-0.65) <0.0001 
        
Hodgkin 
lymphoma 
 
1992-1996 92 44 47.9% (36.9-58.1) 1.62 (1.04-2.53) 1.39 (0.88-2.18)  
1997-2000 111 38 63.3% (53.1-71.8) 1(ref) 1(ref)  
2001-2004 95 24 72.4% (61.5-80.7) 0.67 (0.40-1.12) 0.73 (0.43-1.25)  
2005-2009 163 17 87.2% (79.9-91.9) 0.29 (0.16-0.53) 0.33 (0.18-0.61) <0.0001 
        
Lung 
 
1992-1996 36 28 13.2% (4.2-27.5) 1.10 (0.71-1.69) 1.08 (0.69-1.68)  
1997-2000 107 85 9.9% (4.6-17.7) 1(ref) 1(ref)  
2001-2004 131 94 16.7% (10.1-24.7) 0.95 (0.71-1.28) 0.92 (0.67-1.25)  
2005-2009 172 114 16.4% (9.2-25.5) 0.78 (0.59-1.05) 0.78 (0.57-1.07) 0.3621 
        
Liver 
 
1992-1996 20 15 16.9% (4.2-36.9) 0.79 (0.43-1.46) 0.82 (0.43-1.57)  
1997-2000 39 33 3.5% (0.3-15.2) 1(ref) 1(ref)  
2001-2004 82 58 14.6% (6.5-25.9) 0.70 (0.46-1.08) 0.69 (0.44-1.08)  
2005-2009 171 110 19.2% (11.5-28.5) 0.52 (0.35-0.77) 0.52 (0.34-0.80) 0.0206 
        
Anal 
 
1992-1996 8 4 46.9% (12.0-76.3) 2.17 (0.72-6.54) 3.22 (1.02-10.09)  
1997-2000 54 15 71.3% (56.9-81.6) 1(ref) 1(ref)  
2001-2004 83 25 66.7% (54.7-76.2) 1.04 (0.55-2.00) 1.13 (0.59-2.18)  
2005-2009 112 25 62.9% (47.6-74.9) 1.26 (0.63-2.50) 1.28 (0.63-2.60) 0.2358 
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Table 3. Five-year Kaplan Meier survival rates (95% CI) and death hazard ratios (95% CI) after cancer 
diagnosis between 1997 and 2009. 
*Cox Models adjusted for sex, age, geographic origin and HIV transmission group, HBV and HCV co-infection, AIDS 
status, and CD4 cell count at cancer diagnosis, and the Ptrend for the corresponding models. 
** Cox Models adjusted for sex, age, geographic origin and HIV transmission group, HBV and HCV co-infection, AIDS 
status, CD4 cell count and viral load at cancer diagnosis, and the Ptrend for the corresponding models. 
  
Cancer Diagnosis 
period 
Cases Deaths 5-year survival 
% (95% CI) 
Death hazard  ratio 
adjusted for age 
and sex (95% CI) 
Death hazard 
ratio adjusted for 
all covariates 
except viral load* 
(95% CI) 
Hazard 
Trend* 
P value 
Death hazard ratio 
adjusted for all 
covariates including 
viral load** 
(95% CI) 
Hazard 
Trend** 
P value 
Visceral Kaposi 
sarcoma  
 
1997-2000 176 80 51.7 (43.8-59.1) 1(ref) 1(ref)  1(ref)  
2001-2004 90 30 64.9 (53.6-74.1) 0.68 (0.45-1.05) 1.03 (0.66-1.59)  1.00 (0.64-1.56)  
2005-2009 75 12 82.6 (71.3-89.7) 0.33 (0.18-0.60) 0.56 (0.30-1.04) 0.1618 0.62 (0.33-1.18) 0.3233 
          
Non-visceral 
Kaposi sarcoma 
 
1997-2000 374 67 81.0 (76.5-84.8) 1(ref) 1(ref)  1(ref)  
2001-2004 329 50 83.5 (78.8-87.3) 0.84 (0.58-1.22) 0.95 (0.65-1.38)  0.95 (0.65-1.40)  
2005-2009 315 22 91.9 (87.7-94.6) 0.41 (0.25-0.66) 0.52 (0.32-0.86) 0.0312 0.50 (0.30-0.84) 0.0269 
          
Non-Hodgkin 
lymphoma 
 
1997-2000 516 301 37.8 (33.4-42.2) 1(ref) 1(ref)  1(ref)  
2001-2004 359 171 48.7 (43.2-54.0) 0.75 (0.62-0.91) 0.83 (0.68-1.00)  0.85 (0.70-1.04)  
2005-2009 376 115 65.1 (59.3-70.2) 0.44 (0.36-0.55) 0.54 (0.43-0.67) <0.0001 0.58 (0.46-0.73) <0.0001 
          
Hodgkin 
lymphoma 
 
1997-2000 111 38 63.3 (53.1-71.8) 1(ref) 1(ref)  1(ref)  
2001-2004 95 24 72.4 (61.5-80.7) 0.70 (0.42-1.17) 0.73 (0.42-1.26)  0.79 (0.45-1.39)  
2005-2009 163 17 87.2 (79.9-91.9) 0.32 (0.18-0.58) 0.33 (0.18-0.62) 0.0023 0.36 (0.19-0.69) 0.0071 
          
Lung 
 
1997-2000 107 85 9.9 (4.6-17.7) 1(ref) 1(ref)  1(ref)  
2001-2004 131 94 16.7 (10.1-24.7) 0.94 (0.70-1.26) 0.88 (0.65-1.20)  0.88 (0.64-1.20)  
2005-2009 172 114 16.4 (9.2-25.5) 0.77 (0.58-1.04) 0.75 (0.55-1.02) 0.1739 0.72 (0.51-1.00) 0.1330 
          
Liver 
 
1997-2000 39 33 3.5 (0.3-15.2) 1(ref) 1(ref)  1(ref)  
2001-2004 82 58 14.6 (6.5-25.9) 0.70 (0.45-1.08) 0.71 (0.45-1.12)  0.72 (0.46-1.14)  
2005-2009 171 110 19.2 (11.5-28.5) 0.51 (0.34-0.76) 0.55 (0.35-0.85) 0.0198 0.67 (0.42-1.06) 0.2237 
          
Anal 
 
1997-2000 54 15 71.3 (56.9-81.6) 1(ref) 1(ref)  1(ref)  
2001-2004 83 25 66.7 (54.7-76.2) 1.03 (0.54-1.96) 1.09 (0.57-2.11)  1.13 (0.58-2.20)  
2005-2009 112 25 62.9 (47.6-74.9) 1.23 (0.623-2.44) 1.23 (0.60-2.49) 0.8472 1.35 (0.64-2.84) 0.7239 
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Table 4. Five-year survival rates (95% CI) after cancer diagnosis in the general population and in HIV-
infected individuals in the period 2001-2004, in France 
 5-year Kaplan Meier survival % (95% CI)  
 General population HIV-infected population P value** 
 
Crude survival † 
Age- and sex-
standardized survival* 
 
 
Non-Hodgkin lymphoma (all) 53 (52-54) 74 (72-76) 49 (43-54) <10-4 
Diffuse large B-cell lymphoma 48 (45-51) 70 (65-74) 49 (43-54) <10-4 
Hodgkin lymphoma 79 (75-83) 83 (79-87) 72 (62-81) 0.04 
Lung 13 (13-14) 17 (15-18) 17 (10-25) 1.00 
Liver 10 (9-12) 19 (15-24) 15 (7-26) 0.47 
Anal 56 (52-61) 64 (53-76) 67 (55-76) 0.71 
*Standardization based on the age and sex structure of the HIV-infected patients diagnosed with the same cancer 
**t-test comparing the 5-year survival rates among HIV-infected individuals and the corresponding age- and sex- standardized 
survival rates in the relevant general populations in France 
† From references 21, 22, 23. 
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Supplementary table 1: ICD-9 and ICD-10 cancer codes used in the FHDH  
  FHDH 
 
ICD-9 
≤ 1996 
ICD-10 
>1997 
Kaposi sarcoma 176.x C46.x 
Non-Hodgkin lymphoma (NHL) 200.x 
C83.3, C83.4, 
C83.7, C85.0, 
C85.1, C85.7, 
C85.9 
Lung 162.x C33.x, C44.x 
Hodgkin lymphoma 201.x C81.x 
Liver 155.x C22.x 
Anal 
Validated cases between 1992 
and 2008 and C21.x in 2009 
 
